More Change At GSK's Top, With Vaccines Chief Luc Debruyne Set To Say 'Adieu'
Executive Summary
The head of GSK's vaccines division, Luc Debruyne, is leaving the company at the end of the year.
You may also be interested in...
Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care
Shingrix is likely to replace Merck & Co's Zostavax as the preferred shingles vaccine in the EU and US, following the GSK product’s approval in the US and recent positive opinion in the EU. Sales in major markets could approach $700m by 2025.
GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company," stated GSK's out-going CEO Andrew Witty, as Abbas Hussain decides to leave the company having lost out on the top job, which went to Emma Walmsley. His successor will be AstraZeneca's Luke Miels.
GSK's Vaccines Chief Slaoui To Follow Witty Out The Door
One person definitely not lining up to take over from Sir Andrew Witty when he retires from GlaxoSmithKline PLC in March 2017 is its vaccines chief and former head of R&D Dr. Moncef Slaoui. He is to retire from the company in June 2017.